GE HealthCare plans to pay $2.3 billion in cash to acquire imaging software developer Intelerad, toward the goal of building ...

With much of Moderna’s recent rise tied to its COVID-19 vaccine, the company has struggled to match the sales highs it ...

When Tim Hunt was invited to a meeting with Robert F. Kennedy Jr. in early March, the Department of Health and Human Services ...

Aspen Neuroscience’s cash reserves have been fertilized with a $115 million series C fundraise that will enrich the biotech’s ...

Contineum Therapeutics’ M1 receptor antagonist has failed to move the needle in a phase 2 vision test for patients with a common form of multiple sclerosis. | Contineum Therapeutics’ M1 receptor ...

While the board considers which path to take, it is implementing various “cost-containment and cash conservation measures,” ...

Genetic medicine outfit Ensoma is halving its workforce, with most of the impacted roles related to platform research ...

GSK has picked a novel protein biotech and a genomics biotech as its first collaborators under a $7 billion biobucks deal ...

In January, Exact Sciences CEO Kevin Conroy told us that 2025 was shaping up to be a transformative year for the diagnostics ...

Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. | Pfizer has ...

The Cooper Companies have recently faced pressure from activist investors on two fronts, with pushes to split up their businesses as well as reshape their board of directors.  | Activist investors ...

Novartis may have signed off on the second-largest pharma acquisition of 2025 so far, but as the company’s CEO sees it—it’s never about the price tag. | Novartis may have signed off on the second ...